TGA / PMDA / NMPA · Asia-Pacific
intravitreal — TGA / PMDA / NMPA regulatory status
intravitreal regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 26 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 2.0 mg intravitreal aflibercept | Phase 3 | Regeneron UK | NCT01627249 |
| ADX-2191 (intravitreal methotrexate 0.8%) | Phase 3 | Aldeyra Therapeutics | NCT04136366 |
| Intravitreal Aflibercept Injection (IAI) | Phase 3 | Regeneron UK | NCT01813773 |
| Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Regeneron UK | NCT01363440 |
| Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Regeneron UK | NCT01521559 |
| Intravitreal aflibercept injection [IAI] | Phase 3 | Regeneron UK | NCT02718326 |
| 0.59 mg fluocinolone acetonide intravitreal implant | Phase 2 | Bausch + Lomb | NCT00576459 |
| Brimo PS DDS® | Phase 2 | Allergan Pharmaceuticals International | NCT01080209 |
| Intravitreal Aflibercept Injection | Phase 2 | Regeneron UK | NCT01724554 |
| Intravitreal Aflibercept Injection | Phase 2 | Regeneron UK | NCT01710332 |
| Intravitreal Aflibercept Injection | Phase 2 | Regeneron UK | NCT00789477 |
| Intravitreal Aflibercept Injection | Phase 2 | Regeneron UK | NCT01773954, NCT02462889 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12331099 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 11732024 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 11084865 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 11066458 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 10464992 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 10400025 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 9914763 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 9580489 | VEGF antagonist formulations suitable for intravitreal administration | US |
| 9340594 | VEGF antagonist formulations for intravitreal administration | US |
| 8802107 | VEGF antagonist formulations for intravitreal administration | US |
| 8481046 | VEGF antagonist formulations for intravitreal administration | US |
| 8420619 | Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of intravitreal?
intravitreal currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get intravitreal regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to intravitreal?
This spoke lists 26 published programs associated with intravitreal in our pipeline index.